2024 Minimally Invasive Procedures

| COSMETIC MINIMALLY INVASIVE PROCEDURES* | 2024 | 2023 | % CHANGE 2024 vs 2023 |
|--|------------|------------|--------------------------|
| Neuromodulator injection (Botox [®] , Dysport [®] , Xeomin [®] , Jeaveau [®] , Daxxify [®]) | 9,883,711 | 9,480,949 | 4% |
| Lip augmentation (with injectable materials)‡ | 1,449,565 | 1,439,291 | 1% |
| Noninvasive fat reduction (e.g., Coolsculpting®, Liposonix®, Emsculpt®, Vanquish®, Zerona®, Kybella®) | 447,581 | 745,967 | -40% |
| Nonsurgical skin tightening (e.g., Pelleve®, Thermage®, Ulthera®) | 439,032 | 438,211 | 0% |
| Sclerotherapy | 516,883 | 515,602 | 0% |
| Skin resurfacing (e.g., dermabrasion, chemical peel, ablative/non-ablative lasers, microdermabrasion) | 3,703,305 | 3,501,696 | 6% |
| Skin treatment using lasers (e.g., laser hair removal, IPL treatment, laser tattoo removal, laser treatment of leg veins) | 3,112,056 | 3,101,772 | 0% |
| HA fillers (e.g., Juvederm Ultra®, Ultra Plus®, Voluma®, Volbella®, Vollure®, Restylane Lyft®, Restylane Silk®, Belotero®, Bolvella®, Restylane®) | 5,331,426 | 5,294,603 | 1% |
| Non-HA fillers (e.g., Radiesse [®] , Sculptra [®] , Bellafill [®] , Renuva [®]) | 932,861 | 924,549 | 1% |
| HA fillers for lip augmentation (with injectable materials) \sharp^{**} | 1,589,502 | | |
| Prescribed weight loss medication (e.g., semaglutide, tirzepatide)** | 837,485 | | |
| TOTAL | 28,243,407 | 25,442,640 | 1.5% |

** All procedures include data from ASPS members as well as non-member dermatologists and otolaryngologists.

[‡] "Lip Augmentation with HA Filler" was collected as a distinct procedure for the first time in 2024. In prior years, these procedures may have been reported under "Lip Augmentation with Injectable Materials." The two categories should not be combined due to potential overlap and risk of double counting.